Skip to main content
TipRanks
Go Ultimate75% OFF

TTK Healthcare Limited (TTKHLTCARE) AI Stock Analysis

0 Followers
IN:TTKHLTCARE

TTK Healthcare Limited

(NSE:TTKHLTCARE)

Select Model
Rating:55Neutral
Price Target:INR 1,135.00â–²(2.48% Upside)
Action:reiterated
Date:10/31/26

The strong, low-leverage balance sheet is outweighed by deteriorating cash generation and weaker recent profitability. Negative technical momentum further pressures the score, while valuation remains only moderately supportive.

Positive Factors
Conservative balance sheetVery low leverage and a growing equity base provide financial flexibility, reduce solvency risk, and leave the company better positioned to fund operations or pursue growth. This conservative structure should remain supportive over the next several quarters even if profitability fluctuates.
Negative Factors
Sustained cash burnPersistent negative operating and free cash flow weakens financial flexibility despite the company’s low debt. If cash conversion remains poor, internally generated funds may not adequately support investment, working-capital needs, or shareholder returns over the coming quarters.

TTK Healthcare Limited (TTKHLTCARE) vs. iShares MSCI India ETF (INDA)

-40%-30%-20%-10%0%10%IN:TTKHLTCARE+0.80%INDA-2.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 15.69B
Dividend Yield
0.90%
Average Volume (3M)
3,007
Price to Earnings (P/E)
5.7
Beta (1Y)
0.80
Revenue Growth
11.29%
EPS Growth
317.32%
Country
India
Employees
1,478
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - General

TTK Healthcare Limited Business Overview & Revenue Model

Company Description

TTK Healthcare Limited is a diversified enterprise operating across multiple sectors in India and globally. Its extensive activities encompass animal welfare, offering veterinary therapeutic solutions and feed supplements. The human pharmaceuticals d...

TTK Healthcare Limited Financial Statement Overview

Summary

The balance sheet is strong with low leverage and an expanded equity base, but weaker recent profitability and sustained negative operating and free cash flow materially reduce the financial score.

Income Statement

62Positive

Balance Sheet

82Very Positive

Cash Flow

33Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue9.37B8.57B8.73B7.48B7.25B5.99B
Gross Profit4.13B2.80B5.04B4.07B3.77B3.09B
EBITDA865.03M261.76M1.06B999.35M797.92M412.65M
Net Income2.77B656.80M816.57M628.42M6.40B415.88M
Balance Sheet
Total Assets16.51B13.29B12.81B12.01B11.70B5.59B
Cash, Cash Equivalents and Short-Term Investments10.52B9.75B8.55B8.45B8.47B2.73B
Total Debt283.05M243.78M242.19M228.11M273.29M222.13M
Total Liabilities3.05B2.14B2.16B2.00B2.17B2.29B
Stockholders Equity13.47B11.15B10.65B10.01B9.53B3.30B
Cash Flow
Free Cash Flow0-269.50M-168.16M-153.27M-377.75M385.02M
Operating Cash Flow0-211.48M-39.76M-49.43M-260.76M449.96M
Investing Cash Flow0515.79M201.03M284.94M329.59M-305.47M
Financing Cash Flow0-175.56M-180.81M-219.11M-124.26M-51.77M

TTK Healthcare Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price1107.50

Price Trends

50DMA1017.70Positive
100DMA1028.76Positive
200DMA956.78Positive

Market Momentum

MACD11.02Negative
RSI63.40Neutral
STOCH77.81Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TTKHLTCARE, the sentiment is Positive. The current price of 1107.50 is above the 20-day moving average (MA) of 974.03, above the 50-day MA of 1017.70, and above the 200-day MA of 956.78, indicating a bullish trend. The MACD of 11.02 indicates Negative momentum. The RSI at 63.40 is Neutral, neither overbought nor oversold. The STOCH value of 77.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:TTKHLTCARE.

TTK Healthcare Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:TTKHLTCARE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:CIPLAIN:CIPLA73OutperformINR 1.14T39.45―2.05%-0.74%-46.77%
IN:GLAXOIN:GLAXO73OutperformINR 462.90B40.30―2.08%12.12%20.03%
IN:ABBOTINDIAIN:ABBOTINDIA69NeutralINR 563.78B34.10―2.47%7.21%9.54%
IN:SANOFIIN:SANOFI65NeutralINR 73.89B20.26―3.84%-5.74%2.30%
IN:TTKHLTCAREIN:TTKHLTCARE55NeutralINR 15.65B5.67―0.90%11.29%317.32%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-20%0%20%IN:TTKHLTCAREIN:ABBOTINDIAIN:CIPLAIN:GLAXOIN:SANOFIIN:SANOFICONRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:TTKHLTCARE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:TTKHLTCARETTK Healthcare Limited1107.5018.541.70%
IN:ABBOTINDIAAbbott India Limited26531.60-2513.15-8.65%
IN:CIPLACipla Ltd1414.95-74.96-5.03%
IN:GLAXOGlaxoSmithKline Pharmaceuticals Limited2732.50318.9513.22%
IN:SANOFISanofi India Limited3208.25-1042.67-24.53%
IN:SANOFICONRSanofi Consumer Healthcare India Limited3449.50-1294.14-27.28%

TTK Healthcare Limited Corporate Events

TTK Healthcare Publishes Notice on SEBI Securities Window

Nov 3, 2026

TTK Healthcare Limited is a healthcare-sector company, although the release does not provide details about its primary products, services, or market focus. The company announced that it published a newspaper notice and shared it on LinkedIn regarding...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026